Nxera Pharma Co., Ltd. Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd.

4565

Rank in Stocks #8519
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a... Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Share Price
$11.34
Last synced: 2026-11-13
Market Cap
$1.04B
Change (1 day)
1.27%
Change (1 year)
103.26%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Nxera Pharma Co., Ltd. (4565)
Operating Margin as of November 2026 TTM: 13.59%
According to Nxera Pharma Co., Ltd.'s latest financial reports, its current operating margin (TTM) is 13.59%. At the end of 2025 the company had an operating margin of -27.94%.
Operating Margin history for Nxera Pharma Co., Ltd. from 2005 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 13.59% -148.64%
2025 -27.94% 48.54%
2024 -18.81% -74.79%
2023 -74.62% -513.18%
2022 18.06% -53.69%
2021 39.00% 304.15%
2020 9.65% -8.62%
2019 10.56% -105.46%
2018 -193.28% -394.86%
2017 65.55% 396.97%
2016 13.19% -56.32%
2015 30.20% -17.35%
2014 36.54% -175.08%
2013 -48.67% -78.61%
2012 -227.57% -13.08%
2011 -261.83% 29.83%
2010 -201.67% -91.59%
2009 -2,398.44% 171.27%
2008 -884.14% -1.66%
2007 -899.05% -15.23%
2006 -1,060.57% 47.83%
2005 -717.43% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -114.38%
US
33.87% -97.51%
US
-116.04% -108.54%
US
25.57% -98.12%
AU
31.23% -97.70%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Nxera Pharma Co., Ltd.'s operating margin

What is Nxera Pharma Co., Ltd.'s operating margin?

Nxera Pharma Co., Ltd.'s operating margin is 13.59%, as of Nov 2026.

What was Nxera Pharma Co., Ltd.'s operating margin in 2025?

In 2025, Nxera Pharma Co., Ltd.'s operating margin was -27.94%, compared with -18.81% in 2024.

How has Nxera Pharma Co., Ltd.'s operating margin changed since 2020?

From 2020 to 2025, Nxera Pharma Co., Ltd.'s operating margin was highest in 2021 (39.00%) and lowest in 2023 (-74.62%).

How does Nxera Pharma Co., Ltd.'s operating margin compare with similar companies?

Nxera Pharma Co., Ltd.'s operating margin (13.59%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.